Kezar Life Sciences (KZR) Revenue & Revenue Breakdown
Kezar Life Sciences Revenue Highlights
Latest Revenue (Y)
$7.00M
Kezar Life Sciences Revenue by Period
Kezar Life Sciences Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $7.00M | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2016-12-31 | - | - |
Kezar Life Sciences generated $7.00M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Kezar Life Sciences Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $-5.43M | -177.54% |
2023-09-30 | $7.00M | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | 100.00% |
2017-03-31 | - | - |
Kezar Life Sciences generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Kezar Life Sciences Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
KYMR | Kymera Therapeutics | $78.59M | $10.29M |
NRIX | Nurix Therapeutics | $76.99M | $12.09M |
FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
IKNA | Ikena Oncology | $9.16M | - |
STOK | Stoke Therapeutics | $8.78M | $4.22M |
BOLT | Bolt Biotherapeutics | $7.88M | $1.27M |
KZR | Kezar Life Sciences | $7.00M | - |
IPSC | Century Therapeutics | $2.23M | $771.00K |
STTK | Shattuck Labs | $1.66M | $1.61M |
KROS | Keros Therapeutics | $151.00K | $83.00K |
LYEL | Lyell Immunopharma | $130.00K | $3.00K |
DSGN | Design Therapeutics | - | - |
CGEM | Cullinan Oncology | - | - |
NGM | NGM Biopharmaceuticals | - | $165.00K |
NKTX | Nkarta | - | - |
MLYS | Mineralys Therapeutics | - | - |
LRMR | Larimar Therapeutics | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
SRZN | Surrozen | - | - |
KZR Revenue FAQ
What is Kezar Life Sciences’s yearly revenue?
Kezar Life Sciences's yearly revenue for 2023 was $7M, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. KZR's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Kezar Life Sciences’s quarterly revenue?
Kezar Life Sciences's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). KZR's quarterly revenue for Q4 2023 was $-5.428M, a -177.54% decrease from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Kezar Life Sciences’s revenue growth rate?
Kezar Life Sciences's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.